Category - Markets

Markets

Brookline starts X4 Pharma at buy; PT $21

Brookline Capital Markets launched coverage of X4 Pharmaceuticals (NASDAQ:XFOR) with a “buy” rating and $21 price target. The stock closed at $6.10 on Dec. 16. X4 Pharmaceuticals is focused on diseases resulting from...

December 17, 2020

Markets

Leede Jones Gable starts IntelGenx at speculative buy; PT $1 (Canadian)

Leede Jones Gable initiated coverage of IntelGenx Technologies (TSXV:IGX) with a “speculative buy” rating and price target of $1.00 (Canadian). The stock closed at 37 cents on Dec. 15. IntelGenx is a thin-film...

December 16, 2020

Markets

Leede Jones Gable starts IMV at speculative buy; PT $10.50 (Canadian)

Leede Jones Gable launched coverage of IMV (TSX:IMV) with a “speculative buy” and price target of $10.50 (Canadian). The stock closed at $4.03 on Dec. 15. IMV’s flagship technology platform is the lipid-based water-free...

December 16, 2020

Markets

Leede Jones Gable starts Liminal BioSciences at hold; PT $4

Leede Jones Gable initiated coverage of Liminal BioSciences (NASDAQ:LMNL) with a “hold” rating and $4 price target. The stock closed at $4.20 on Dec. 15. Liminal is a plasma products and anti-fibrotic small molecule...

December 16, 2020

Markets

Leede Jones Gable starts Oncolytics Biotech at speculative buy; PT $8.50 (Canadian)

Leede Jones Gable launched coverage of Oncolytics Biotech (TSX:ONC) with a “speculative buy” rating and $8.50 (Canadian) price target. The stock closed at $3.07 on Dec. 15. Oncolytics is a cancer-focused virus-based...

December 16, 2020

Markets

Leede Jones Gable starts Medical Facilities at buy; PT $10.50 (Canadian)

Leede Jones Gable initiated coverage of Medical Facilities (TSX:DR) with a “buy” rating and price target of $10.50 (Canadian). The stock closed at $7.32 on Dec. 15. Medical Facilities owns a majority stake in several U...

December 16, 2020

Markets

Leede Jones Gable starts CareRx at buy; PT $6.50 (Canadian)

Leede Jones Gable initiated coverage of CareRx (TSX:CRRX) with a “buy” rating and one-year price target of $6.50 (Canadian). The stock was quoted at $3.75, up 26 cents, near mid-day on Dec. 15. CareRx, formerly known as...

December 15, 2020

Markets

Leede Jones Gable starts Sernova at speculative buy; PT $1 (Canadian)

Leede Jones Gable launched coverage of Sernova (TSXV:SVA) with a “speculative buy” rating and price target of $1.00 (Canadian). The stock was quoted at 44 cents in early trading on Dec. 15. “We are positive on the...

December 15, 2020

Markets

Mackie Research ups Medexus Pharma PT to $9 (Canadian) from $6.30

Mackie Research Capital raised its price target for Medexus Pharmaceuticals (TSXV:MDP; OTCQX:MEDXF) to $9 (Canadian) from $6.30, citing positive momentum in sales of the company’s key drugs. The stock closed at $6.11 on...

December 15, 2020

Markets

SVB Leerink ups TCR2 Therapeutics PT to $41 from $28

SVB Leerink raised its price target for TCR2 Therapeutics (NASDAQ:TCRR) to $41 from $28, citing positive interim data from the ongoing Phase 1 portion of the TC-210 Phase 1/2 clinical trial for mesothelin-expressing...

December 15, 2020

Category - Markets

Brookline starts X4 Pharma at buy; PT $21

Leede Jones Gable starts IntelGenx at speculative buy; PT $1 (Canadian)

Leede Jones Gable starts IMV at speculative buy; PT $10.50 (Canadian)

Leede Jones Gable starts Liminal BioSciences at hold; PT $4

Leede Jones Gable starts Oncolytics Biotech at speculative buy; PT $8.50 (Canadian)

Leede Jones Gable starts Medical Facilities at buy; PT $10.50 (Canadian)

Leede Jones Gable starts CareRx at buy; PT $6.50 (Canadian)

Leede Jones Gable starts Sernova at speculative buy; PT $1 (Canadian)

Mackie Research ups Medexus Pharma PT to $9 (Canadian) from $6.30

SVB Leerink ups TCR2 Therapeutics PT to $41 from $28

General

More